{"id":426264,"date":"2010-03-14T09:04:51","date_gmt":"2010-03-14T13:04:51","guid":{"rendered":"http:\/\/blogs.jwatch.org\/hiv-id-observations\/?p=802"},"modified":"2010-03-14T09:04:51","modified_gmt":"2010-03-14T13:04:51","slug":"mrsa-bacteremia-question-redux-%e2%80%94-and-the%c2%a0%e2%80%9canswer%e2%80%9d","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/426264","title":{"rendered":"MRSA Bacteremia Question Redux \u2014 and the\u00a0\u201cAnswer\u201d"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-thumbnail wp-image-805\" title=\"test\" src=\"http:\/\/blogs.jwatch.org\/hiv-id-observations\/wp-content\/uploads\/2010\/03\/test-150x150.jpg\" alt=\"test\" width=\"150\" height=\"150\" \/>As noted here, I recently had to answer a question on management of MRSA bacteremia as part of an every-10-year cycle of test-taking.<\/p>\n<p>(For more on that joyous process, read this interesting debate\u00a0<a href=\"http:\/\/content.nejm.org\/cgi\/content\/full\/362\/10\/948\" >here in the<\/a><a href=\"http:\/\/content.nejm.org\/cgi\/content\/full\/362\/10\/948\" > New England Journal of Medicine.<\/a>)<\/p>\n<p>The question seemed to have no obvious right answer, so I did what one is\u00a0<em>explicitly allowed to do<\/em> in this phase of the process\u00a0&#8211; in other words, I asked some experts for their advice.<\/p>\n<p>As a reminder, the case is a guy with positive blood cultures for MRSA (vancomycin MIC 2.0) on hospital day 4 despite receiving vancomycin (trough 15) and having undergone resection of a mycotic aneursym on hospital day 3.<\/p>\n<p>Choices were: \u00a01) continue current vancomcyin dose; 2) increase vancomycin to achieve trough of 20; 3) change to daptomycin; 4) change to linezolid.<\/p>\n<p>Expert Number One said the following:<\/p>\n<blockquote>\n<p>What a terrible question. \u00a0A classic case of &#8220;what is the writer thinking and how much does he\/she know?&#8221; 4 is clearly wrong, but I wouldn&#8217;t be surprised to hear that this is what they want. \u00a0If the MIC is really 2, \u00a0you need a trough of 40, which is not an option, so 2 is wrong. \u00a0Given that he is only 5 days out and average duration of bacteremia in this setting is 7 days or so, you could consider 1 with reassessment in 2 or 3 days (but this is not really given here) and with MIC of 2, probably won&#8217;t work. \u00a0That leaves 3 by default, but with MIC of 2, \u00a0there is a significant possibility of heteroresistance to bothvanco and dapto. \u00a0A terrible question. \u00a0I wouldn&#8217;t know how to guess what they want!<\/p>\n<\/blockquote>\n<p>And Expert Number Two &#8212; who kindly allowed me to cite as Dr.\u00a0Myoung-don Oh, who is the corresponding author of <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19569970\" >this paper<\/a> &#8212; generously offered:<\/p>\n<blockquote>\n<p>I think there are several issues to resolve.<\/p>\n<p>#1. Is the patient failing on VCM therapy?\u00a0I think it is too early to declare VCM failure in this case.\u00a0(1)The median duration of MRSA bacteremia(or mycotic aneurysm) is &gt;4 days\u00a0(2)\u00a0Even if we choose an optimum antibiotic, MRSA bacteremia would persist if infected focus is not removed). In this case, the aneurysm was resected on HD#3. Therefore, I would rather wait 2 more days to see if MRSA bacteremia persist.<\/p>\n<p><span id=\"more-802\"><\/span><\/p>\n<p>#2. VCM MIC=2 can predict worse prognosis?\u00a0Previous studies have shown that higher VCM MIC was associated with poor outcome.\u00a0CID 2008;46:193-200;\u00a0JCM 2004;42:2398-402;\u00a0Arch Intern Med 2006;166:2138-44.\u00a0However, I think we still need further data on this issue, because other variables, especially host conditions and site of infection, also affect the outcome.<\/p>\n<p>#3. With VCM MIC=2(assume that it is confirmed by \u201cgold standard test\u201d rather than E-test), would you like to increase VCM dose?\u00a0It seems to me that rationale for higher dose VCM is favorable AUC\/MIC.\u00a0Recent guideline (CID, 2009) also recommends VCM trough level of 15-20mg\/L, because this gives you AUC\/MIC greater than 400 in case that MIC= 1 ug\/mL.\u00a0Problems of this recommendation include (1) correlation between PK\/PD parameters &amp; clinical outcome still need further data, (2) increased renal toxicity, (3) AUC\/MIC not achievable if VCM MIC&gt;2. (Actually, strength of the recommendation is BIII).<\/p>\n<p># 4. How about daptomycin for this bacteremic patient?\u00a0Daptomycin is non-inferior to VCM for initial therapy of MRSA bacteremia.\u00a0However, if you switch to daptomycin, it\u2019s a salvage regimen. And I am not aware of any clinical data regarding salvage therapy. As VCM MIC =2, I am afraid that cross-resistance between VCM &amp; daptomycin might compromise this salvage therapy.<\/p>\n<p>In conclusion, I\u2019d rather wait for 2 more days with the same VCM treatment.<\/p>\n<\/blockquote>\n<p>Which certainly made\u00a0<em>me <\/em>feel better. \u00a0Since the answer the examiners wanted was daptomycin.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/HivAndIdObservations\/~4\/uV0xP8JEAlA\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>As noted here, I recently had to answer a question on management of MRSA bacteremia as part of an every-10-year cycle of test-taking. (For more on that joyous process, read this interesting debate\u00a0here in the New England Journal of Medicine.) The question seemed to have no obvious right answer, so I did what one is\u00a0explicitly [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-426264","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/426264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=426264"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/426264\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=426264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=426264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=426264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}